{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T02:47:58Z","timestamp":1777430878631,"version":"3.51.4"},"reference-count":83,"publisher":"Asia Pacific Academy of Ophthalmology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia Pac J Ophthalmol (Phila)"],"published-print":{"date-parts":[[2017]]},"DOI":"10.22608\/apo.201837","type":"journal-article","created":{"date-parts":[[2018,4,9]],"date-time":"2018-04-09T11:31:32Z","timestamp":1523273492000},"source":"Crossref","is-referenced-by-count":11,"title":["Anti-VEGF for ROP and Pediatric Retinal Diseases"],"prefix":"10.22608","member":"9895","published-online":{"date-parts":[[2017]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3928\/23258160-20170630-06","article-title":"The epidemiology of retinopathy of prematurity in the United States","volume":"48","author":"Ludwig","year":"2017","unstructured":"1. Ludwig CA, Chen TA, Hernandez-Boussard T, et al. The epidemiology of retinopathy of prematurity in the United States. Ophthalmic Surg Lasers Imaging Retina. 2017;48:553\u2012562.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010.","volume":"74","author":"Blencowe","year":"2013","unstructured":"2. Blencowe H, Lawn JE, Vazquez T, et al. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res. 2013;74(Suppl 1):35\u201249.","journal-title":"Pediatr Res","ISSN":"https:\/\/id.crossref.org\/issn\/0031-3998","issn-type":"print"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/bjo.2007.126201","article-title":"Retinopathy of prematurity in the United States","volume":"92","author":"Lad","year":"2008","unstructured":"3. Lad EM, Nguyen TC, Morton JM, et al. Retinopathy of prematurity in the United States. Br J Ophthalmol. 2008;92:320\u2012325.","journal-title":"Br J Ophthalmol"},{"key":"ref3","unstructured":"2. Smith BT, Tasman WS. Retinopathy of prematurity: late complications in the baby boomer generation (1946-1964). Trans Am Ophthalmol Soc. 2005; 103:225\u2012234; discussion 234\u2012226."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.","volume":"106","year":"1988","unstructured":"5. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1988;106:471\u2012479.","journal-title":"Arch Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9950","issn-type":"print"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial.","volume":"121","year":"2003","unstructured":"6. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial. Arch Ophthalmol. 2003;121:1684\u20121694.","journal-title":"Arch Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9950","issn-type":"print"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2741\/1056","article-title":"Animal models of oxygen-induced retinopathy","volume":"8","author":"Madan","year":"2003","unstructured":"7. Madan A, Penn JS. Animal models of oxygen-induced retinopathy. Front Biosci. 2003;8:1030\u20121043.","journal-title":"Front Biosci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/S0021-9258(17)41787-X","article-title":"Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin.","volume":"269","author":"Goldberg","year":"1994","unstructured":"8. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem. 1994;269:4355\u20124359.","journal-title":"J Biol Chem","ISSN":"https:\/\/id.crossref.org\/issn\/0021-9258","issn-type":"print"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner HA","year":"2011","unstructured":"9. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603\u2012615.","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"CD009734","DOI":"10.1002\/14651858.cd009734.pub2","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.","volume":"2","author":"Sankar","year":"2016","unstructured":"10. Sankar MJ, Sankar J, Mehta M, et al. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2016;2:CD009734.","journal-title":"Cochrane Database Syst Rev","ISSN":"https:\/\/id.crossref.org\/issn\/1469-493X","issn-type":"print"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","article-title":"Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab","volume":"35","author":"Chen","year":"2015","unstructured":"11. Chen SN, Lian I, Hwang YC, et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina. 2015;35:667\u2012674.","journal-title":"Retina"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.ophtha.2014.01.001","article-title":"Planned preterm delivery and treatment of retinal neovascularization in Norrie disease","volume":"121","author":"Sisk","year":"2014","unstructured":"12. Sisk RA, Hufnagel RB, Bandi S, et al. Planned preterm delivery and treatment of retinal neovascularization in Norrie disease. Ophthalmology. 2014;121:1312\u20121313.","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/bjophthalmol-2011-300141","article-title":"Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction","volume":"96","author":"Ramasubramanian","year":"2012","unstructured":"13. Ramasubramanian A, Shields CL. Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction. Br J Ophthalmol. 2012;96:356\u2012359.","journal-title":"Br J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1097\/IAE.0b013e3181679bf6","article-title":"Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen).","volume":"28","author":"Quiram","year":"2008","unstructured":"14. Quiram PA, Drenser KA, Lai MM, et al. Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen). Retina. 2008;28:S8\u2012S12.","journal-title":"Retina","ISSN":"https:\/\/id.crossref.org\/issn\/0275-004X","issn-type":"print"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"ME","year":"2012","unstructured":"15. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367:2515\u20122526.","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10456-007-9066-0","article-title":"Retinopathy of prematurity","volume":"10","author":"Chen","year":"2007","unstructured":"16. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10: 133\u2012140.","journal-title":"Angiogenesis"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1167\/iovs.08-2584","article-title":"Through the eyes of a child: understanding retinopathy through ROP. The Friedenwald Lecture.","volume":"49","author":"Smith","year":"2008","unstructured":"17. Smith LE. Through the eyes of a child: understanding retinopathy through ROP. The Friedenwald Lecture. Invest Ophthalmol Vis Sci. 2008;49: 5177\u20125182.","journal-title":"Invest Ophthalmol Vis Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0146-0404","issn-type":"print"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang","year":"2017","unstructured":"18. Zhang G, Yang M, Zeng J, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2017;37:710\u2012717.","journal-title":"Retina"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1111\/aos.12339","article-title":"Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.","volume":"92","author":"Moran","year":"2014","unstructured":"19. Moran S, O'Keefe M, Hartnett C, et al. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Acta Ophthalmol. 2014;92:e496\u2012e497.","journal-title":"Acta Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/1755-375X","issn-type":"print"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","unstructured":"20. Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327\u20121333.","journal-title":"JAMA Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5301\/ejo.5000166","article-title":"Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II","volume":"22","author":"Autrata","year":"2012","unstructured":"21. Autrata R, Krejcirova I, Senkova K, et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol. 2012;22:687\u2012694.","journal-title":"Eur J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1136\/bjo.2007.132597","article-title":"Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial","volume":"92","author":"Singerman","year":"2008","unstructured":"22. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008;92:1606\u20121611.","journal-title":"Br J Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","unstructured":"23. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351: 2805\u20122816.","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","unstructured":"24. Hwang CK, Hubbard GB, Hutchinson AK, et al. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122:1008\u20121015.","journal-title":"Ophthalmology"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","unstructured":"25. Tahija SG, Hersetyati R, Lam GC, et al. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol. 2014;98:507\u2012512.","journal-title":"Br J Ophthalmol"},{"key":"ref25","unstructured":"10. Wu WC, Kuo HK, Yeh PT, et al. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan. Am J Ophthalmol. 2013;155:150\u2012158, e151."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","article-title":"Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II","volume":"28","author":"Mintz-Hittner HA","year":"2008","unstructured":"27. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28:831\u2012838.","journal-title":"Retina"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","unstructured":"28. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179\u20122182.","journal-title":"Ophthalmology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay","year":"2017","unstructured":"29. Gunay M, Sukgen EA, Celik G, et al. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017;42:462\u2012469.","journal-title":"Curr Eye Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/OPTH.S33372","article-title":"Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept","volume":"6","author":"Stewart","year":"2012","unstructured":"30. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175\u20121186.","journal-title":"Clin Ophthalmol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF trap","volume":"92","author":"MW","year":"2008","unstructured":"31. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol. 2008;92:667\u2012668.","journal-title":"Br J Ophthalmol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000364809","article-title":"Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity","volume":"53","author":"AG","year":"2015","unstructured":"32. Salman AG, Said AM. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res. 2015;53:15\u201220.","journal-title":"Ophthalmic Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","unstructured":"33. Lepore D, Quinn GE, Molle F, et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology. 2014;121:2212\u20122219.","journal-title":"Ophthalmology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","article-title":"Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan","volume":"118","author":"WC","year":"2011","unstructured":"34. Wu WC, Yeh PT, Chen SN, et al. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology. 2011;118:176\u2012183.","journal-title":"Ophthalmology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","unstructured":"35. Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016;123:1845\u20121855.","journal-title":"Ophthalmology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","unstructured":"36. Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000\u20121006.","journal-title":"Arch Ophthalmol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/eye.2012.111","article-title":"Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity.","volume":"26","author":"Lee","year":"2012","unstructured":"37. Lee BJ, Kim JH, Heo H, et al. Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity. Eye (Lond). 2012;26:903\u2012909; quiz 910.","journal-title":"Eye (Lond )","ISSN":"https:\/\/id.crossref.org\/issn\/0950-222X","issn-type":"print"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaapos.2010.05.011","article-title":"Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity","volume":"14","author":"Jang","year":"2010","unstructured":"38. Jang SY, Choi KS, Lee SJ. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. J AAPOS. 2010;14:457\u2012459.","journal-title":"J AAPOS"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","article-title":"Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice.","volume":"118","author":"Moshfeghi","year":"2011","unstructured":"39. Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology. 2011;118:1227\u20121228.","journal-title":"Ophthalmology","ISSN":"https:\/\/id.crossref.org\/issn\/0161-6420","issn-type":"print"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","unstructured":"40. Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015;35:675\u2012680.","journal-title":"Retina"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.5935\/0004-2749.20150090","article-title":"Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity","volume":"78","author":"Erol","year":"2015","unstructured":"41. Erol MK, Coban DT, Sari ES, et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Arq Bras Oftalmol. 2015;78:340\u2012343.","journal-title":"Arq Bras Oftalmol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3109\/02713683.2015.1084643","article-title":"Effects of intravitreal ranibizumab in the treatment of retinopathy of prematurity in Chinese infants","volume":"41","author":"Yi","year":"2016","unstructured":"42. Yi Z, Su Y, Zhou Y, et al. Effects of intravitreal ranibizumab in the treatment of retinopathy of prematurity in Chinese infants. Curr Eye Res. 2016;41:1092\u20121097.","journal-title":"Curr Eye Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3928\/23258160-20161130-03","article-title":"Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment","volume":"47","author":"Chuluunbat","year":"2016","unstructured":"43. Chuluunbat T, Chan RV, Wang NK, et al. Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment. Ophthalmic Surg Lasers Imaging Retina. 2016;47:1095\u20121105.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e304","DOI":"10.1111\/aos.12055","article-title":"Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection.","volume":"91","author":"Xu","year":"2013","unstructured":"44. Xu Y, Zhang Q, Kang X, et al. Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection. Acta Ophthalmol. 2013;91:e304\u2012e310.","journal-title":"Acta Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/1755-375X","issn-type":"print"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1097\/IAE.0b013e3181ca146b","article-title":"Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.","volume":"30","author":"Kychenthal","year":"2010","unstructured":"45. Kychenthal A, Dorta P. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina. 2010;30:S32\u2012S36.","journal-title":"Retina","ISSN":"https:\/\/id.crossref.org\/issn\/0275-004X","issn-type":"print"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","unstructured":"46. Honda S, Hirabayashi H, Tsukahara Y, et al. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246:1061\u20121063.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":"Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity","volume":"24","author":"Zepeda-Romero","year":"2010","unstructured":"47. Zepeda-Romero LC, Liera-Garcia JA, Gutierrez-Padilla JA, et al. Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity. Eye (Lond). 2010;24:931\u2012933.","journal-title":"Eye (Lond)"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","article-title":"312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study","volume":"37","author":"Lorenz","year":"2017","unstructured":"48. Lorenz B, Stieger K, Jager M, et al. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: a longitudinal fluorescein angiographic study. Retina. 2017; 37:97\u2012111.","journal-title":"Retina"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/aos.12266","article-title":"Intravitreal low-dosage bevacizumab for retinopathy of prematurity","volume":"92","author":"Harder","year":"2014","unstructured":"49. Harder BC, von Baltz S, Jonas JB, et al. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol. 2014;92:577\u2012581.","journal-title":"Acta Ophthalmol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/IAE.0000000000001209","article-title":"Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity","volume":"37","author":"WC","year":"2017","unstructured":"50. Wu WC, Shih CP, Lien R, et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2017;37:694\u2012701.","journal-title":"Retina"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","article-title":"Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity","volume":"133","author":"WC","year":"2015","unstructured":"51. Wu WC, Lien R, Liao PJ, et al. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol. 2015;133:391\u2012397.","journal-title":"JAMA Ophthalmol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","unstructured":"52. Wallace DK, Kraker RT, Freedman SF, et al. Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol. 2017;135:654\u2012656.","journal-title":"JAMA Ophthalmol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3928\/01913913-20150216-01","article-title":"Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years","volume":"52","author":"MA","year":"2015","unstructured":"53. Klufas MA, Chan RV. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years. J Pediatr Ophthalmol Strabismus. 2015;52:77\u201284.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0161-6420(01)00695-9","article-title":"Outcomes after laser therapy for threshold retinopathy of prematurity","volume":"108","author":"Foroozan","year":"2001","unstructured":"54. Foroozan R, Connolly BP, Tasman WS. Outcomes after laser therapy for threshold retinopathy of prematurity. Ophthalmology. 2001;108:1644\u20121646.","journal-title":"Ophthalmology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","article-title":"Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes.","volume":"26","author":"Kychenthal","year":"2006","unstructured":"55. Kychenthal A, Dorta P, Katz X. Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina. 2006;26:S11\u2012S15.","journal-title":"Retina","ISSN":"https:\/\/id.crossref.org\/issn\/0275-004X","issn-type":"print"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1136\/bjo.2008.140657","article-title":"Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study","volume":"92","author":"Kusaka","year":"2008","unstructured":"56. Kusaka S, Shima C, Wada K, et al. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study. Br J Ophthalmol. 2008;92:1450\u20121455.","journal-title":"Br J Ophthalmol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/eye.2014.172","article-title":"Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes.","volume":"28","author":"Chen","year":"2014","unstructured":"57. Chen YH, Chen SN, Lien RI, et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (Lond). 2014;28:1080\u20121086; quiz 1087.","journal-title":"Eye (Lond )","ISSN":"https:\/\/id.crossref.org\/issn\/0950-222X","issn-type":"print"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.ophtha.2012.02.040","article-title":"Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity","volume":"119","author":"WC","year":"2012","unstructured":"58. Wu WC, Lin RI, Shih CP, et al. Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity. Ophthalmology. 2012;119:1907\u20121916.","journal-title":"Ophthalmology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e0129383","DOI":"10.1371\/journal.pone.0129383","article-title":"A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity.","volume":"10","author":"Pertl","year":"2015","unstructured":"59. Pertl L, Steinwender G, Mayer C, et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One. 2015; 10:e0129383.","journal-title":"PLoS One","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"F327","DOI":"10.1136\/archdischild-2012-302365","article-title":"Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening Database report number 5.","volume":"98","author":"Jalali","year":"2013","unstructured":"60. Jalali S, Balakrishnan D, Zeynalova Z, et al. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening Database report number 5. Arch Dis Child Fetal Neonatal Ed. 2013;98:F327\u2012F333.","journal-title":"Arch Dis Child Fetal Neonatal Ed","ISSN":"https:\/\/id.crossref.org\/issn\/1359-2998","issn-type":"print"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1167\/iovs.09-4425","article-title":"Long-term tolerability and serum concentration of bevacizumab (Avastin) when injected in newborn rabbit eyes","volume":"51","author":"WC","year":"2010","unstructured":"61. Wu WC, Lai CC, Chen KJ, et al. Long-term tolerability and serum concentration of bevacizumab (Avastin) when injected in newborn rabbit eyes. Invest Ophthalmol Vis Sci. 2010;51:3701\u20123708.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref61","unstructured":"19. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327\u2012333, e321."},{"issue":"March","key":"ref62","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1542\/peds.2015-3218","article-title":"Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity.","author":"Morin","year":"2016","unstructured":"63. Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. March 17, 2016. [Epub ahead of print].","journal-title":"Pediatrics","ISSN":"https:\/\/id.crossref.org\/issn\/0031-4005","issn-type":"print"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/IAE.0b013e318275394a","article-title":"Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up","volume":"33","author":"Martinez-Castellanos","year":"2013","unstructured":"64. Martinez-Castellanos MA, Schwartz S, Hernandez-Rojas ML, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina. 2013;33:329\u2012338.","journal-title":"Retina"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment.","volume":"11","author":"Lien","year":"2016","unstructured":"65. Lien R, Yu MH, Hsu KH, et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS One. 2016;11:e0148019.","journal-title":"PLoS One","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1038\/eye.2010.127","article-title":"A population-based study of Coats disease in the United Kingdom II: investigation, treatment, and outcomes","volume":"24","author":"Mulvihill","year":"2010","unstructured":"66. Mulvihill A, Morris B. A population-based study of Coats disease in the United Kingdom II: investigation, treatment, and outcomes. Eye (Lond). 2010;24:1802\u20121807.","journal-title":"Eye (Lond)"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0002-9394(00)00883-7","article-title":"Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture","volume":"131","author":"Shields","year":"2001","unstructured":"67. Shields JA, Shields CL, Honavar SG, et al. Clinical variations and complications of Coats disease in 150 cases: the 2000 Sanford Gifford Memorial Lecture. Am J Ophthalmol. 2001;131:561\u2012571.","journal-title":"Am J Ophthalmol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/bjo.55.5.289","article-title":"Electron microscopical study of Coat's disease","volume":"55","author":"Tripathi","year":"1971","unstructured":"68. Tripathi R, Ashton N. Electron microscopical study of Coat's disease. Br J Ophthalmol. 1971;55:289\u2012301.","journal-title":"Br J Ophthalmol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1746-1596-1-24","article-title":"Clinical-histopathological correlation in a case of Coats' disease","volume":"1","author":"Fernandes","year":"2006","unstructured":"69. Fernandes BF, Odashiro AN, Maloney S, et al. Clinical-histopathological correlation in a case of Coats' disease. Diagn Pathol. 2006;1:24.","journal-title":"Diagn Pathol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/hmg\/8.11.2031","article-title":"Coats' disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis","volume":"8","author":"Black","year":"1999","unstructured":"70. Black GC, Perveen R, Bonshek R, et al. Coats' disease of the retina (unilateral retinal telangiectasis) caused by somatic mutation in the NDP gene: a role for norrin in retinal angiogenesis. Hum Mol Genet. 1999;8: 2031\u20122035.","journal-title":"Hum Mol Genet"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1442-9071.2006.01314.x","article-title":"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity","volume":"34","author":"Dickinson","year":"2006","unstructured":"71. Dickinson JL, Sale MM, Passmore A, et al. Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clin Exp Ophthalmol. 2006;34:682\u2012688.","journal-title":"Clin Exp Ophthalmol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00417-007-0559-8","article-title":"Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium","volume":"245","author":"Sun","year":"2007","unstructured":"72. Sun Y, Jain A, Moshfeghi DM. Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium. Graefes Arch Clin Exp Ophthalmol. 2007;245:1387\u20121388.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00417-010-1366-1","article-title":"Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab","volume":"248","author":"YG","year":"2010","unstructured":"73. He YG, Wang H, Zhao B, et al. Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2010;248:1519\u20121521.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/0301-4738.58480","article-title":"Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats' disease in children","volume":"58","author":"Kaul","year":"2010","unstructured":"74. Kaul S, Uparkar M, Mody K, et al. Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of Coats' disease in children. Indian J Ophthalmol. 2010;58:76\u201278.","journal-title":"Indian J Ophthalmol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/IAE.0b013e3181c2e0b7","article-title":"The effect of intravitreal bevacizumab in the treatment of Coats disease in children","volume":"30","author":"Lin","year":"2010","unstructured":"75. Lin CJ, Hwang JF, Chen YT, et al. The effect of intravitreal bevacizumab in the treatment of Coats disease in children. Retina. 2010;30:617\u2012622.","journal-title":"Retina"},{"key":"ref75","first-page":"397","article-title":"Retinoblastoma: concerning its initiation and treatment.","volume":"6","author":"Luo","year":"2013","unstructured":"76. Luo C, Deng YP. Retinoblastoma: concerning its initiation and treatment. Int J Ophthalmol. 2013;6:397\u2012401.","journal-title":"Int J Ophthalmol","ISSN":"https:\/\/id.crossref.org\/issn\/2222-3959","issn-type":"print"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"5326","DOI":"10.3892\/ol.2017.6827","article-title":"Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an in vitro and in vivo model","volume":"14","author":"Zhang","year":"2017","unstructured":"77. Zhang Q, Cheng Y, Huang L, et al. Inhibitory effect of carboplatin in combination with bevacizumab on human retinoblastoma in an in vitro and in vivo model. Oncol Lett. 2017;14:5326\u20125332.","journal-title":"Oncol Lett"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/archophthalmol.2009.386","article-title":"Expression of vascular endothelial growth factor in retinoblastoma","volume":"128","author":"Arean","year":"2010","unstructured":"78. Arean C, Orellana ME, Abourbih D, et al. Expression of vascular endothelial growth factor in retinoblastoma. Arch Ophthalmol. 2010;128: 223\u2012229.","journal-title":"Arch Ophthalmol"},{"key":"ref78","first-page":"5725","article-title":"Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies.","volume":"7","author":"Youssef","year":"2014","unstructured":"79. Youssef NS, Said AM. Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies. Int J Clin Exp Pathol. 2014;7:5725\u20125737.","journal-title":"Int J Clin Exp Pathol","ISSN":"https:\/\/id.crossref.org\/issn\/1936-2625","issn-type":"print"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"e0177337","DOI":"10.1371\/journal.pone.0177337","article-title":"Analysis of aqueous humor concentrations of cytokines in retinoblastoma.","volume":"12","author":"Cheng","year":"2017","unstructured":"80. Cheng Y, Zheng S, Pan CT, et al. Analysis of aqueous humor concentrations of cytokines in retinoblastoma. PLoS One. 2017;12:e0177337.","journal-title":"PLoS One","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"e33456","DOI":"10.1371\/journal.pone.0033456","article-title":"Inhibitory activity of bevacizumab to differentiation of retinoblastoma cells.","volume":"7","author":"Heo","year":"2012","unstructured":"81. Heo JW, Kim JH, Cho CS, et al. Inhibitory activity of bevacizumab to differentiation of retinoblastoma cells. PLoS One. 2012;7:e33456.","journal-title":"PLoS One","ISSN":"https:\/\/id.crossref.org\/issn\/1932-6203","issn-type":"print"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000099247","article-title":"VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma","volume":"39","author":"Jia","year":"2007","unstructured":"82. Jia RB, Zhang P, Zhou YX, et al. VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res. 2007;39:108\u2012115.","journal-title":"Ophthalmic Res"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/archopht.126.7.953","article-title":"Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma","volume":"126","author":"Lee","year":"2008","unstructured":"83. Lee SY, Kim DK, Cho JH, et al. Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol. 2008;126: 953\u2012958.","journal-title":"Arch Ophthalmol"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T17:48:30Z","timestamp":1660844910000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/apjoo\/Abstract\/2018\/05000\/Anti_VEGF_for_ROP_and_Pediatric_Retinal_Diseases.4.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":83,"URL":"https:\/\/doi.org\/10.22608\/apo.201837","relation":{},"ISSN":["2162-0989","2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"},{"value":"2162-0989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}